| 916 |
Centers for Disease Control and Prevention |
Html |
en |
Interim Estimates of 2013-14 Seasonal Influenza VaccineEffectiveness - United States, February 2014 |
Brendan Flannery, PhD1, Swathi N. Thaker, PhD1, Jessie Clippard, MPH1, Arnold S. Monto, MD2, Suzanne E. |
| influenza | 0.910213 |
| U.S. Influenza Vaccine | 0.654703 |
| influenza infection | 0.550936 |
| United States | 0.538934 |
| influenza pandemic viruses | 0.593334 |
| influenza pH1N1 virus | 0.57366 |
| inactivated influenza vaccines | 0.55073 |
| pH1N1 influenza viruses | 0.579116 |
| seasonal influenza vaccination | 0.630938 |
| Influenza vaccination coverage | 0.588032 |
| influenza antiviral medication | 0.587552 |
| influenza virus infection | 0.608575 |
| previous influenza seasons | 0.569391 |
| self-rated health | 0.514967 |
| vaccination status | 0.553218 |
| influenza patients | 0.575421 |
| seasonal influenza vaccine | 0.803831 |
| influenza illness | 0.599304 |
| pH1N1 influenza virus | 0.619406 |
| seasonal influenza vaccines | 0.606267 |
| Flu VE Network | 0.512742 |
| 2013-14 influenza vaccine | 0.585044 |
| acute respiratory illness | 0.586374 |
| influenza vaccine | 0.906488 |
|
| influenza activity | 0.628686 |
| influenza vaccines | 0.610865 |
| seasonal influenza | 0.81736 |
| patient vaccination status | 0.518633 |
| influenza virus infections | 0.579437 |
| influenza vaccination | 0.699514 |
| subtyped influenza | 0.55321 |
| persons | 0.534299 |
| medical visits | 0.508589 |
| influenza vaccine effectiveness | 0.663366 |
| influenza vaccine locator | 0.588395 |
| annual seasonal influenza | 0.557496 |
| Influenza Division | 0.541527 |
| influenza viruses | 0.711209 |
| annual influenza vaccination | 0.633162 |
| study site | 0.53225 |
| Early antiviral treatment | 0.532211 |
| influenza virus | 0.678937 |
| predominant influenza virus | 0.563625 |
| illness onset | 0.61173 |
| influenza season vaccination | 0.614208 |
| influenza cases | 0.556867 |
| influenza diagnostic tests | 0.565715 |
|
CLICK HERE |
| 4522 |
Centers for Disease Control and Prevention |
Html |
en |
Reconstruction of the 1918 Influenza Pandemic Virus |
CDC researchers and their colleagues have successfully reconstructed the influenza virus that caused the 1918-19 flu pandemic, which killed as many as 50 million people worldwide. |
| 1918-like H1N1 virus | 0.644858 |
| Armed Forces Institute | 0.619031 |
| Biosafety Committee review | 0.617046 |
| contemporary human influenza | 0.657081 |
| influenza subtype | 0.614838 |
| gene segments | 0.611987 |
| CDC | 0.644074 |
| current annual influenza | 0.641234 |
| Involving Noncontemporary Human | 0.609267 |
| human influenza viruses | 0.777393 |
| CDC/NIH publication Biosafety | 0.612496 |
| Laboratory Work Involving | 0.619515 |
| pandemic influenza viruses | 0.717498 |
| virus gene products | 0.62821 |
| Animal Biosafety Level | 0.622853 |
| similar pandemic virus | 0.696797 |
| candidate reference virus | 0.64064 |
| Work Involving Noncontemporary | 0.61704 |
| Technical Advisory Committee | 0.609277 |
| influenza research | 0.611073 |
| HHS select agents | 0.617192 |
| pandemic viruses | 0.625929 |
| animal influenza viruses | 0.657335 |
| current influenza vaccine | 0.683485 |
|
| Toxins Technical Advisory | 0.610183 |
| 1918-like virus | 0.628718 |
| Influenza experts | 0.613615 |
| Interim CDC-NIH Recommendation | 0.609971 |
| pandemic influenza virus | 0.869793 |
| Biosafety Level Laboratory | 0.673623 |
| pandemic influenza strain | 0.663971 |
| antiviral drugs | 0.618323 |
| biosafety level | 0.763779 |
| select agent program | 0.613451 |
| select agent | 0.642301 |
| new influenza virus | 0.698591 |
| similar virus | 0.620906 |
| Influenza Pandemic Virus | 0.799057 |
| influenza viruses | 0.80971 |
| Intra-governmental Select Agents | 0.615167 |
| replication competent forms | 0.607386 |
| influenza virus | 0.984334 |
| Level Laboratory Work | 0.62583 |
| Noncontemporary Human Influenza | 0.688759 |
| biosafety levels | 0.632484 |
| appropriate biosafety measures | 0.606356 |
| select agents | 0.638178 |
|
CLICK HERE |
| 5134 |
Centers for Disease Control and Prevention |
Html |
en |
Alaska Activities to Prevent HAIs |
null |
| MPEG | 0.446113 |
| funding | 0.634686 |
| monthly update | 0.806007 |
| email address | 0.973252 |
| different file formats | 0.743548 |
| Affordable Care Act | 0.755504 |
| Epidemiology | 0.597099 |
| recent work | 0.786869 |
|
| PDF | 0.439171 |
| infectious disease | 0.830694 |
| PPT | 0.456191 |
| Laboratory Capacity | 0.936956 |
| Infectious Diseases | 0.944175 |
| DOC | 0.444472 |
| page | 0.491246 |
| ELC | 0.644161 |
|
CLICK HERE |
| 7014 |
Centers for Disease Control and Prevention |
Html |
en |
Section 906 of the Federal Food, Drug, and Cosmetic Act -General Provisions Respecting Control of Tobacco Products |
null |
| extent | 0.524934 |
| benefits | 0.519782 |
| amendment | 0.524802 |
| manufacturing restrictions | 0.640632 |
| access | 0.521102 |
| controls | 0.518659 |
| Secretary | 0.629003 |
| methods | 0.518721 |
| pesticide chemical residues | 0.707918 |
| protection | 0.541398 |
| advertising | 0.542153 |
| distribution | 0.521184 |
| packing | 0.519366 |
| type | 0.51879 |
| subparagraph | 0.518899 |
| current good manufacturing | 0.685198 |
| hazard analysis | 0.605587 |
| public health | 0.819442 |
| tolerance | 0.521388 |
| Constitution | 0.51898 |
| tobacco product | 0.976857 |
|
| process | 0.518559 |
| accordance | 0.523772 |
| control point methodology | 0.689023 |
| testing | 0.518707 |
| nonusers | 0.519695 |
| finding | 0.519981 |
| raw tobacco | 0.700159 |
| preproduction design validation | 0.703461 |
| respect | 0.521778 |
| users | 0.519711 |
| population | 0.518898 |
| manufacture | 0.518621 |
| sale | 0.5212 |
| risks | 0.520163 |
| performance | 0.518528 |
| regulation | 0.618136 |
| regulations | 0.54742 |
| General | 0.545898 |
| facilities | 0.518675 |
| account | 0.519623 |
|
CLICK HERE |
| 7071 |
Centers for Disease Control and Prevention |
Html |
en |
Global Health - Argentina |
null |
| Content source | 0.422709 |
| HHS | 0.297574 |
| list Skip | 0.74332 |
| endorsement | 0.291872 |
| CDC | 0.271556 |
| non-federal site | 0.4688 |
|
| Notice | 0.270187 |
| sponsors | 0.241885 |
| page options Skip | 0.947337 |
| information | 0.241652 |
| employees | 0.242118 |
|
CLICK HERE |
| 8969 |
Centers for Disease Control and Prevention |
Html |
en |
Develop SMART Objectives - Evaluate a CoP - Resource Kit |
null |
| additional questions | 0.503054 |
| important outcomes | 0.500634 |
| practice | 0.487491 |
| following table | 0.614962 |
| activity | 0.425727 |
| CoP | 0.792729 |
| Communities | 0.460752 |
| new products | 0.497955 |
| table lists questions | 0.603483 |
| CoP collaborations | 0.563442 |
| new ideas | 0.50132 |
| swot analysis | 0.606231 |
| constraints | 0.44982 |
| measurement | 0.422094 |
| CoPs | 0.569176 |
| CoP translate objectives | 0.732678 |
| SWOT Analysis Tool | 0.596905 |
| timeframe | 0.428134 |
| Numbers | 0.422117 |
| standard evaluation | 0.498776 |
| Leaders | 0.487671 |
| strong action verbs | 0.600633 |
| SMART Objectives Template | 0.840169 |
| external factors | 0.499543 |
|
| smart objectives | 0.93171 |
| sample questions | 0.494425 |
| public health | 0.508444 |
| goals | 0.558997 |
| limitations | 0.421943 |
| means | 0.442012 |
| sample evaluation objectives | 0.626681 |
| following questions | 0.525654 |
| cost | 0.421924 |
| strategies | 0.42319 |
| time frame | 0.505979 |
| Resources section | 0.503998 |
| change | 0.422694 |
| CoP environment | 0.565499 |
| time-based objectives | 0.556656 |
| resources | 0.513719 |
| objective lead | 0.56163 |
| innovations | 0.442146 |
| Innovation Tracking Tool | 0.762714 |
| activities | 0.475696 |
| SMART ones | 0.52835 |
| evaluation process | 0.494961 |
| Concrete | 0.423927 |
|
CLICK HERE |
| 10672 |
Centers for Disease Control and Prevention |
Html |
en |
VX - Nerve Agent'First Hours |
The CERC training program educates people on the principles and application of crisis and emergency risk communication when responding to a public health emergency. |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 10713 |
Centers for Disease Control and Prevention |
Html |
en |
Short and Extended Messages'Smallpox'First Hours |
The CERC training program educates people on the principles and application of crisis and emergency risk communication when responding to a public health emergency. |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 11936 |
Centers for Disease Control and Prevention |
Html |
en |
Incidence of Hansen's Disease - United States,1994-2011 |
Leisha Nolen, MD, PhD1, Dana Haberling, MSPH1, David Scollard, MD, PhD2, Richard Truman, PhD2, Alfonso Rodriguez-Lainz, PhD, DVM3, Laura Blum, MPH4, David Blaney, MD1 (Author affiliations at end of text). |
| rate trends | 0.439085 |
| foreign-born persons | 0.759199 |
| new HD | 0.488252 |
| symptom onset | 0.506062 |
| Leisha Nolen | 0.45237 |
| normal incubation period | 0.44637 |
| severely debilitating disease | 0.453015 |
| Zoonotic Infectious Diseases | 0.438041 |
| HD morbidity | 0.494459 |
| chronic skin disorders | 0.441193 |
| Federated States | 0.435799 |
| highest rate | 0.477108 |
| World Health Organization | 0.444454 |
| HD trends | 0.491922 |
| diagnosis | 0.531326 |
| annual incidence | 0.460878 |
| primary care clinicians | 0.443494 |
| symptoms | 0.470365 |
| chronic skin conditions | 0.476336 |
| Delayed diagnosis | 0.433013 |
| lower rate | 0.439075 |
| HD patients | 0.480349 |
| U.S.-born persons | 0.567173 |
| United States | 0.922675 |
|
| median delay | 0.460929 |
| maculopapular skin lesions | 0.445885 |
| reddish skin patches | 0.448828 |
| new diagnoses | 0.494303 |
| U.S. Census Bureau | 0.475721 |
| mean period | 0.449999 |
| Current Population Survey | 0.445763 |
| rate | 0.521523 |
| annual incidence rate | 0.460436 |
| cases | 0.461578 |
| population estimates | 0.442126 |
| American Community Survey | 0.444071 |
| rate ratios | 0.440931 |
| newly diagnosed HD | 0.521687 |
| average annual rate | 0.485037 |
| early diagnosis | 0.433526 |
| HD diagnosis | 0.525356 |
| bacterium Mycobacterium leprae | 0.451902 |
| average rate | 0.439634 |
| higher rate | 0.437998 |
| public health problem | 0.4451 |
| 1994–1996 | 0.435371 |
| HD | 0.748074 |
| M. leprae | 0.443956 |
|
CLICK HERE |
| 15451 |
Centers for Disease Control and Prevention |
Html |
en |
Questions About Zika |
Information on Zika virus. Provided by the U.S. Centers for Disease Control and Prevention. |
| mosquito bites | 0.493746 |
| Zika infection | 0.518209 |
| recent travel | 0.470534 |
| Zika virus | 0.803525 |
| territorial health departments | 0.465468 |
| severe birth defects | 0.470147 |
| recent Zika virus | 0.522381 |
| muscle pain | 0.465468 |
| Zika prevention page | 0.493365 |
| pregnant women | 0.587849 |
| Zika-related pregnancy complications | 0.466171 |
| red eyes | 0.46648 |
| past Zika infection | 0.512496 |
| -registered insect repellents | 0.46674 |
| EPA-registered insect repellents | 0.465836 |
| Zika virus disease | 0.578854 |
| current Zika outbreaks | 0.492886 |
| insect repellents | 0.50818 |
| symptoms | 0.591955 |
| Aedes albopictus | 0.486008 |
| insect repellent | 0.468592 |
| Zika virus outbreak | 0.50815 |
| Zika active transmission | 0.495198 |
| infected Aedes species | 0.50514 |
| cdc zika travel | 0.615028 |
|
| sex partners | 0.513036 |
| United States | 0.500827 |
| future Zika infections | 0.497775 |
| Local mosquito-borne spread | 0.464779 |
| Zika virus infection | 0.621486 |
| mild symptoms | 0.554865 |
| Zika | 0.920864 |
| zika travel notice | 0.61047 |
| severe brain defects | 0.540211 |
| birth defect | 0.477736 |
| Zika stays | 0.468528 |
| following ingredients | 0.46413 |
| sexual transmission | 0.513538 |
| joint pain | 0.466857 |
| bites | 0.515022 |
| people | 0.505384 |
| birth defects | 0.472204 |
| infected mosquito | 0.488588 |
| lemon eucalyptus | 0.509649 |
| healthcare provider | 0.510388 |
| Zika cautionary areas | 0.499449 |
| risk | 0.57936 |
| Zika symptoms | 0.498486 |
| Zika virus testing | 0.516437 |
|
CLICK HERE |